Roche to Pay Igen in Licensing Case
- Share via
Switzerland’s Roche Holding Ltd. must pay $501 million in damages to Igen International Inc. in a licensing dispute over blood-testing technology used in Roche’s diagnostic equipment, jurors ruled.
Jurors in federal court in Greenbelt, Md., found that officials of Roche’s diagnostic unit deliberately underpaid royalties on the technology, used to test bodily fluids for cancer and thyroid problems.
Although the jury’s ruling returns the testing-technology license to Igen, company officials have agreed not to make Roche officials stop using the system until all appeals are exhausted.
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.
